نتایج جستجو برای: moxifloxacin hydrochloride

تعداد نتایج: 46374  

Journal: :Antimicrobial agents and chemotherapy 2004
Chiu-Yeung Chan Carrie Au-Yeang Wing-Wai Yew Chi-Chiu Leung Augustine F B Cheng

Postantibiotic effects (PAEs) of rifapentine, isoniazid, and moxifloxacin against Mycobacterium tuberculosis ATCC 27294 were studied using a radiometric culture system. Rifapentine at 20 mg/liter gave the longest PAE (104 h) among the drugs used alone. The combinations of rifapentine plus isoniazid, rifapentine plus moxifloxacin, and isoniazid plus moxifloxacin gave PAEs of 136.5, 59.0, and 8.3...

Journal: :The Journal of antimicrobial chemotherapy 2006
Silvano Esposito Silvana Noviello Gioacchino D'Errico Gaetano Motta Desiderio Passali Claudia Aimoni Stefano Pilucchi Stefania Fallani Maria Iris Cassetta Teresita Mazzei Andrea Novelli

OBJECTIVES The antibacterial spectrum of moxifloxacin includes all the major respiratory pathogens, and its pharmacokinetics demonstrate high peak concentrations in plasma as well as at respiratory sites. Nevertheless, tonsillar tissue concentrations have never been investigated. In this study we determined the moxifloxacin concentrations in plasma and tonsillar tissue after the administration ...

2010
Sanjay Sethi Paul W Jones Marlize Schmitt Theron Marc Miravitlles Ethan Rubinstein Jadwiga A Wedzicha Robert Wilson

BACKGROUND Acute exacerbations contribute to the morbidity and mortality associated with chronic obstructive pulmonary disease (COPD). This proof-of-concept study evaluates whether intermittent pulsed moxifloxacin treatment could reduce the frequency of these exacerbations. METHODS Stable patients with COPD were randomized in a double-blind, placebo-controlled trial to receive moxifloxacin 40...

Journal: :Transactions of the American Ophthalmological Society 2004
Seenu M Hariprasad William E Mieler Gaurav K Shah Kevin J Blinder Rajendra S Apte Nancy M Holekamp Matthew A Thomas Jingduan Chi Randall A Prince

PURPOSE To determine penetration of moxifloxacin 0.5% into human aqueous and vitreous via topical and collagen shield routes of administration. METHODS Moxifloxacin 0.5% was administered prior to vitrectomy surgery through one of three routes: topical drops every 2 hours for 3 days, versus topical drops every 6 hours for 3 days, versus delivery using a 24-hour dissolvable cross-linked corneal...

2013
Steven A Nielsen Marguerite B McDonald Parag A Majmudar

BACKGROUND To evaluate the safety of besifloxacin ophthalmic suspension 0.6% when used in laser-assisted in situ keratomileusis (LASIK) prophylactic antibiotic regimens. METHODS Retrospective surveillance of LASIK surgery cases where besifloxacin ophthalmic suspension 0.6% or moxifloxacin ophthalmic solution 0.5% were prescribed as prophylactic medications. Surgeons from nine US surgical cent...

Journal: :International Journal of Chronic Obstructive Pulmonary Disease 2007
Marc Miravitlles

Bacteria are isolated in more than 50% of exacerbations of chronic bronchitis (CB) and chronic obstructive pulmonary disease (COPD). The most prevalent respiratory pathogens include Gram-positive (Streptococcus pneumoniae) and Gram-negative (Haemophilus influenzae, Moraxella catarrhalis) microorganims. Moxifloxacin is a fourth-generation fluoroquinolone that has been shown to be effective again...

2014
Jiana SHI Huimin XU

A 73-year-old female patient developed a generalized tonic-clonic seizure on the 6th day after treatment with moxifloxacin 400 mg daily intravenously for appendicitis. This patient had atrial fibrillation and history of a surgery for intracerebral hemorrhage, with impaired renal function and liver function, but without history of seizures. Moxifloxacin was discontinued and switched to cefuroxim...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید